Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Cambridge NanoTech is a leading provider of Atomic Layer Deposition (ALD) systems, a technology used to create ultra-thin, highly uniform films at the atomic scale. While the company's primary markets include semiconductors and energy, its technology is increasingly vital in the life sciences for developing biocompatible coatings on medical implants and protective layers for diagnostic sensors. The company's flagship products, such as the Savannah and Phoenix ALD systems, allow researchers to engineer surfaces with unprecedented precision, facilitating advancements in drug delivery and tissue engineering. Founded in 2003 and based in Cambridge, Massachusetts, the company was acquired by Veeco Instruments in 2012. Today, its legacy continues as part of Veeco's nanotechnology division, supporting innovation in both industrial and biomedical applications.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Cambridge NanoTech.